Introduction
============

Osteosarcoma is the most commonly diagnosed primary malignant bone tumor, and can lead to tumor-related mortality among children and adolescents ([@b1-mmr-19-05-4205]). Osteosarcoma is the most common form of bone and soft tissue malignant tumor, and is characterized by high tumor cell proliferation, high mortality and rapid metastasis ([@b2-mmr-19-05-4205]). Unfortunately, the prognosis of patients with metastatic osteosarcoma remains poor ([@b3-mmr-19-05-4205]). In addition, only a slight improvement in the survival rate of osteosarcoma patients has been achieved even following the development of novel therapeutic technologies, such as radiotherapy, adjuvant chemotherapy and surgery ([@b4-mmr-19-05-4205],[@b5-mmr-19-05-4205]). To date, there are few available biomarkers to manage the tumor burden and also the treatment response for osteosarcoma. Thus, prognostic assessment and early diagnosis of osteosarcoma are of great importance. Therefore, the prognostic evaluation and early diagnosis of osteosarcoma are important for the initiation of early treatment and thus patient survival can be improved accordingly.

Chromobox protein homolog 3 (CBX3) belongs to the heterochomatin protein 1 (HP1) family, which is involved in transcriptional activation or repression, cell differentiation and growth and epigenetic modifications ([@b6-mmr-19-05-4205],[@b7-mmr-19-05-4205]). Additionally, it has been reported that CBX3 is upregulated in many cancer types, which is of great significance for the development of cancer and the regulation of growth-related genes ([@b8-mmr-19-05-4205],[@b9-mmr-19-05-4205]). Thus, it is expected that CBX3 plays an extremely significant role in the progression of tumors. However, the functional role of CBX3 in osteosarcoma progression, tumorigenesis and prognosis requires further elucidation.

The present study is the first to investigate the functional role and prognostic value of CBX3 in osteosarcoma. This study demonstrated that there was a high expression of CBX3 in sarcoma and osteosarcoma tissues. In addition, the clinical significance of CBX3 expression in human osteosarcoma was also explored. Meanwhile, the impact of CBX3 on cell cycle distribution, apoptosis and proliferation of osteosarcoma cells was also investigated.

Materials and methods
=====================

### Bioinformatic analysis through Oncomine databases

Oncomine database (<https://www.oncomine.org>) was used for the assessment of the differences in CBX3 mRNA expression between matched normal tissues and sarcoma tissues, based on the following filtering conditions: P-value \<0.0001, gene rank (top 10%), fold change \>2, data type (mRNA), analysis type (cancer vs. normal analysis) and gene (CBX3).

### Patients and tissue samples

A total of 98 osteosarcoma patients (56 males and 42 females; mean age, 18 years) who underwent initial surgery at the First Affiliated Hospital of Xinxiang Medical University (Xinxiang, China) between January 2008 and December 2017 were enrolled in this study. All patients were diagnosed with osteosarcoma at the Pathology Department of the First Affiliated Hospital of Xinxiang Medical University. Written informed consent for the participation in this study was obtained from all the patients. The Medical Ethics Committee of the First Affiliated Hospital of Xinxiang Medical University approved the use of the samples. All specimens were immediately frozen and stored in liquid nitrogen (−196°C). Every patient was treatment-naïve until the resection.

### Cell lines

The human osteosarcoma cell line MG63 was purchased from the Shanghai Cell Bank (Shanghai, China). Dulbecco\'s modified Eagle\'s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.) were used to culture all the cells at 37°C in 5% CO~2~.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay

TRIzol was used to extract all the RNA from the osteosarcoma cells and tissues according to the manufacturer\'s protocol (Shanghai Invitrogen Biotechnology Co., Ltd., Shanghai, China). The qPCR was used to detect the expression levels of CBX3 mRNA by One-Step RT-PCR kit (Takara Bio, Inc., Otsu, Japan) based on the manufacturer\'s protocol. The thermocycling conditions were as follows: Initial denaturation at 95°C for 30 sec, followed by 40 amplification cycles of 95°C for 5 sec and 60°C for 34 sec. The CBX3 primers were purchased from Shanghai Genechem Co., Ltd. (Shanghai, China). The internal reference was glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

The primers used in the present study were as follows: CBX3 forward, 5′-TGGCCTCCAACAAAACTACA-3′ and reverse, 5′-TCCCATTCACTACACGTCGA-3′; and GAPDH forward, 5′-GGAGTCAACGGATTTGGTCGTAT-3′ and reverse, 5′-AGCCTTCTCCATGGTGGTGAAGAC-3′. The 2^−ΔΔCq^ method ([@b10-mmr-19-05-4205]) was used to quantify the CBX3 mRNA expression levels. Then, the GAPDH mRNA expression level was used to normalize it.

### Transfection of osteosarcoma MG63 cells

The negative control siRNA (NC siRNA) and CBX3 small interfering RNA (siRNA) were provided by Shanghai GeneChem Biotechnology Co., Ltd. (Shanghai, China). The sequences of the siRNAs used in the present study were: Si-CBX3, 5′-GCGTTTCTTAACTCTCAGAAA-3′ and negative control (NC), 5′-TTCTCCGAACGTGTCACGT-3′. The cells were cultured to 60% confluence, and were then plated in a 6-well plate at the density of 5×10^5^/well. The cells were then transfected with 50 nM NC siRNA or CBX3 siRNA. Transfection was performed using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. qPCR and western blotting were used to validate the transfection efficiency of CBX3 siRNA 48 h after transfection.

### Western blot analysis

The cells and tissues were harvested according to the manufacturer\'s instructions. A BCA protein assay kit (Pierce; Thermo Fisher Scientific, Inc.) was used to determine the protein concentration. Afterwards, equal amounts of total protein (50 µg/lane) were separated by 12.5% SDS-PAGE, and transferred onto polyvinylidene difluoride membranes. Membranes were blocked with 5% skim milk powder in TBS-Tween (0.1%) for 2 h at room temperature and then incubated with a 1:800 dilution of rabbit anti-CBX3 (cat. no. ab10480) antibody or a 1:2,500 dilution of rabbit anti-GAPDH (cat. no. ab9485) antibody (Abcam, Cambridge, MA, USA). Additionally, the secondary antibody was horseradish peroxidase-conjugated goat anti-rabbit IgG (1:10,000; cat. no. ab6721; Abcam). The positive bands were detected using the Enhanced Chemiluminescence plus western blotting detection system (GE Healthcare, Chicago, IL, USA). Band intensities were quantified by densitometry using ImageJ Software version 1.6 (National Institutes of Health, Bethesda, MD, USA). GAPDH was applied as the internal reference for the normalization of the expression levels of CBX3.

### Cell proliferation assay and flow cytometry

After being transfected with NC siRNA or CBX3 siRNA, the cells at the exponential phase were cultured in 96-wells at a density of 4×10^3^ cells/well. The Cell-Counting Kit-8 (CCK-8; Beijing Transgen Biotech Co., Ltd., Beijing, China) was used to determine the cell proliferation ability according to the manufacturer\'s instructions.

In addition, the MG63 cells were transfected with NC siRNA or CBX3 siRNA and incubated at 37°C for 48 h. Afterwards, the transfected osteosarcoma cells were harvested and washed twice with phosphate-buffered saline (PBS). Then, 75% ice-cold ethanol was used for the fixation. Afterwards, there was management of the cells via the Cell Cycle Staining kit (Multi Sciences Biotech Co., Ltd., Hangzhou, China). The MG63 cells were harvested and incubated at room temperature for 15 min with FITC-conjugated Annexin V and propidium iodide (PI) to determine the impact of CBX3 siRNA on cell apoptosis according to the manufacturer\'s instructions (Annexin V-FITC Apoptosis Detection Kit; Nanjing KeyGen Biotech Co., Ltd., Nanjing, China). Flow cytometry was performed using a FACScan flow cytometer and the data were analyzed using the BD CellQuest software (version 5.1; BD Biosciences, San Jose, CA, USA).

### Statistical analysis

The SPSS 22.0 software (IBM Corp., Armonk, NY, USA) was applied for the processing of the data and also for the statistical analysis. The data values are expressed as mean ± standard deviation (SD). The Chi-square test was used to analyze the enumeration data. The Student\'s t-test was used for the analysis of the measurement data between two groups. The one-way analysis of variance (ANOVA) was used for group comparisons. Kaplan-Meier analysis was used to evaluate the survival. The log-rank test was used to compare the differences in the survival rates. In addition, the multivariate and univariate analysis applied the Cox regression analysis. Statistical significance was set at a P-value of \<0.05.

Results
=======

### CBX3 is overexpressed in human sarcoma tissues

To ascertain whether CBX3 was expressed differentially between the sarcoma tissues and the matched sarcoma tissues, the Oncomine database was analyzed to examine the CBX3 mRNA expression levels. There were altogether 4 analyses satisfying the inclusion standards. The statistics of Barretina sarcoma was chosen because of the presence of the majority of the research subjects. No statistics concerning the function of osteosarcoma is currently available. However, it was revealed from the research that in comparison with the normal adipose tissues, there was markedly higher CBX3 mRNA expression level in other sarcoma types, such as pleomorphic liposarcoma (t=12.188, P\<0.001; [Fig. 1D](#f1-mmr-19-05-4205){ref-type="fig"}), myxofibrosarcoma (t=15.331, P\<0.001; [Fig. 1C](#f1-mmr-19-05-4205){ref-type="fig"}), myxoid/round cell liposarcoma (t=15.989, P\<0.001; [Fig. 1B](#f1-mmr-19-05-4205){ref-type="fig"}) and dedifferentiated liposarcoma (t=2.270, P\<0.001; [Fig. 1A](#f1-mmr-19-05-4205){ref-type="fig"}).

### CBX3 is upregulated in human osteosarcoma tissues

Afterwards, the qPCR assay was used for the detection of the CBX3 expression levels in 98 osteosarcoma samples and the corresponding non-carcinoma bone tissues. Generally, [Table I](#tI-mmr-19-05-4205){ref-type="table"} summarizes the clinicopathological features of the osteosarcoma patients. As shown in [Fig. 2](#f2-mmr-19-05-4205){ref-type="fig"}, a significantly higher level of CBX3 mRNA was observed in the osteosarcoma tissues compared with the level in the matched adjacent bone tissues (t=19.21, P\<0.001). It was suggested from these findings that CBX3 may be involved in osteosarcoma progression.

### Correlation of CBX3 expression with clinicopathological characteristics in osteosarcoma

Based on the statistical analysis, osteosarcoma patients were classified into a low CBX3 expression group (n=49) and a high CBX3 expression group (n=49). Associations of CBX3 expression with the clinicopathological features were then analyzed. As shown in [Table II](#tII-mmr-19-05-4205){ref-type="table"}, there was a strong association between CBX3 expression and distant metastasis (P=0.022), clinical stage (P\<0.001) and tumor size (P=0.043), but not with recurrence (P\>0.05), lymph node metastasis, response to chemotherapy, pathological differentiation, anatomic location, sex and age. Additionally, it was revealed from the Spearman correlation analysis ([Table III](#tIII-mmr-19-05-4205){ref-type="table"}) of the correlation between the clinicopathological features and CBX3 that there was a strong correlation among distant metastasis (P=0.022), clinical stage (P\<0.0001) and tumor size (P=0.044).

### High CBX3 expression is associated with poor prognosis in osteosarcoma

To investigate the prognostic value of CBX3 expression in osteosarcoma, long-rank test and Kaplan-Meier analysis were conducted. It was shown from the results that there was an association between high CBX3 expression and shorter OS (P\<0.0001; [Fig. 3A](#f3-mmr-19-05-4205){ref-type="fig"}) and DFS (P=0.003; [Fig. 3B](#f3-mmr-19-05-4205){ref-type="fig"}) of the osteosarcoma patients compared with those with low CBX3 expression.

Afterwards, multivariate and univariate Cox regression was used for the collection and analysis of all the clinical data. It was demonstrated that CBX3 expression serves as an independent prognostic factor that could impact osteosarcoma patient OS ([Table IV](#tIV-mmr-19-05-4205){ref-type="table"}) and DFS ([Table V](#tV-mmr-19-05-4205){ref-type="table"}).

### CBX3 siRNA inhibits CBX3 expression in human osteosarcoma MG63 cells

To investigate the function of CBX3 in osteosarcoma, NC siRNA and CBX3 siRNA expressing GFP were transfected into human osteosarcoma MG63 cells. The qPCR and western blotting were used to analyze the knockdown efficiency. After the cells were transfected, the expression levels of CBX3 mRNA (t=6.868, P=0.0001; [Fig. 4B](#f4-mmr-19-05-4205){ref-type="fig"}) and CBX3 protein (t=5.095, P=0.0009; [Fig. 4A](#f4-mmr-19-05-4205){ref-type="fig"}) in the MG63 cells of the CBX3 siRNA group were significantly lower compared with these levels in the NC siRNA group.

### Downregulation of CBX3 expression markedly inhibits the growth of osteosarcoma MG63 cells

To explore the impact of CBX3 on the growth of osteosarcoma cells, CCK-8 assay was conducted after osteosarcoma MG63 cells were transfected with NC siRNA or CBX3 siRNA. As shown in [Fig. 4C](#f4-mmr-19-05-4205){ref-type="fig"}, the proliferation rate of the MG63 cells was markedly inhibited by the knockdown of CBX3 expression in comparison with the NC siRNA group. Furthermore, on day 4 (t=4.612, P=0.0017) and day 5 (t=8.017, P\<0.0001), there was an obvious reduction in the cell growth of the CBX3 siRNA group *in vitro*. Thus, CBX3 knockdown prevented the growth of osteosarcoma MG63.

### Inhibition of CBX3 induces cell cycle arrest at G0/G1 phase and increases the apoptosis of osteosarcoma MG63 cells

There is a direct associated between proliferation and the distribution of the cell cycle. Therefore, we explored the cell cycle distribution of MG63 cells after CBX3 was downregulated. Flow cytometric analysis was used to assess the cell cycle in MG63 cells. As shown in [Fig. 5A](#f5-mmr-19-05-4205){ref-type="fig"}, the number of cells in the G0 and G1 phases had an increase of 14.60% (t=5.163, P=0.0067) in the CBX3 siRNA group while there was a decrease by 9.30% (t=8.664, P=0.001) in the S phase and a decrease by 5.30% (t=4.743, P=0.009) in the G2/M phase following the knockout of CBX3. Moreover, the impact of CBX3 knockdown on the apoptosis of osteosarcoma MG63 cells was also explored. There was evidently higher percentage of apoptotic MG63 cells in the CBX3 siRNA group in comparison with the NC siRNA group (t=7.834, P=0.0014; [Fig. 5B](#f5-mmr-19-05-4205){ref-type="fig"}).

The results demonstrated that knockdown of CBX3 expression can suppress the proliferation of MG63 cells via the increase in the proportion of cells in the G0 and G1 phases of the cell cycle and a decrease in the percentage of cells during the G2/M and S phases. In addition, knockdown of CBX3 expression induced apoptosis.

Discussion
==========

The conserved chromatin binding proteins comprising the heterochomatin protein 1 (HP1) family, are directly associated with the methylated H3K9 (the methyl groups of histone H3 at lysine 9) promoter region, and therefore, take part in the heterochromatin silencing of gene expression ([@b7-mmr-19-05-4205]). The aberrant expression of HP1 can result in different human diseases, such as organism defects and cancer progression ([@b11-mmr-19-05-4205]). Generally, chromobox protein homolog 3 (CBX3)-encoded heterochromatin protein 1γ (HP1γ) is a paralog of HP1.

High CBX3 expression has been reported in various types of cancers. CBX3 may be involved in the progression of cancer. Therefore, it is a potential cancer treatment target ([@b12-mmr-19-05-4205]). Fan *et al* reported that colon cancer cell proliferation can be improved by targeting p21 and CDK6 in colorectal cancer (CRC) ([@b6-mmr-19-05-4205]). Chang and colleagues found that CBX3 is overexpressed in non-small cell lung cancer (NSCLC) ([@b13-mmr-19-05-4205]). Thus, it was hypothesized that CBX3 expression is a predictor of poor prognosis of patients suffering from NSCLC. Slezak *et al* ([@b14-mmr-19-05-4205]) found a positive correlation between Ki-67 expression and the CBX3 expression level, which could predict an unfavorable prognosis of prostate cancer patients. However, the function of CBX3 in the prognosis and progression of osteosarcoma has not yet been fully demonstrated.

Firstly, the present study investigated the function and also the clinical significance of CBX3 in osteosarcoma patients via the clinical data of osteosarcoma patients and public expression profiles. The results showed that the expression levels of CBX3 were significantly upregulated in sarcoma tissues in comparison with those in the normal adipose tissues. Then, high expression of CBX3 was noted in human osteosarcoma tissues in comparison with the corresponding adjacent bone tissues. Third, it was indicated from the statistical analysis that there was an evident correlation between CBX3 expression levels and a high distant metastasis rate, high clinical stage and a larger tumor size. It was confirmed by further univariate and multivariate analyses that CBX3 can be used as a potential prognostic biomarker for osteosarcoma patient.

Additionally, the CBX3 siRNA was designed and used for the transfection of MG63 cells in order to detect whether the cell cycle distribution, apoptosis and proliferation of the osteosarcoma cells can be impacted by downregulation of the gene expression levels of CBX3 *in vitro*. It was shown that the proliferation of MG63 cells was significantly prohibited by the knockdown of CBX3 expression via the increase in the percentage of cells during the G0 and G1 phases and a decrease in the proportion of the cells in the G2/M and S phases. In addition, apoptosis was induced. Nevertheless, further evaluation and validation must be further conducted to evaluate the function of CBX3 in cell lines of osteosarcoma and the explicit system implied by such association.

In conclusion, our findings demonstrated that CBX3 is of great significance in the prognosis and progression of human osteosarcoma. CBX3 is highly expressed in human osteosarcoma tissues. The dismal prognosis of patients suffering from osteosarcoma can be predicted by high CBX3 expression. In addition, the proliferation of osteosarcoma MG63 cells was inhibited following the downregulation of CBX3 expression. This was realized by induction of cell apoptosis and cell cycle arrest. Thus, CBX3 can be valuable as an independent potential prognostic biomarker for patients suffering from osteosarcoma.
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![CBX3 is overexpressed in sarcoma tissues. CBX3 mRNA expression is significantly upregulated in (A) dedifferentiated liposarcoma, (B) myxoid/round cell liposarcoma, (C) myxofibrosarcoma and (D) pleomorphic liposarcoma compared with that in paired normal tissues. Data were collected and analyzed via the Oncomine database. CBX3, chromobox protein homolog 3.](MMR-19-05-4205-g00){#f1-mmr-19-05-4205}

![CBX3 expression level in osteosarcoma tissues was significantly higher than this level in corresponding non-cancerous bone tissues. \*P\<0.05 compared with the paired adjacent bone tissues. CBX3, chromobox protein homolog 3.](MMR-19-05-4205-g01){#f2-mmr-19-05-4205}

![Kaplan-Meier curves showing the survival of osteosarcoma patients with high and low CBX3 expression levels. (A) OS curves stratified by CBX3 expression in osteosarcoma patients. (B) DFS curves stratified by CBX3 expression in osteosarcoma patients. CBX3, chromobox protein homolog 3. OS, overall survival; DFS, disease-free survival.](MMR-19-05-4205-g02){#f3-mmr-19-05-4205}

![CBX3 siRNA was constructed to inhibit the proliferation of osteosarcoma cells. The knockdown efficiency of CBX3 was assessed by (A) western blotting and (B) qPCR assay, respectively. (C) CCK-8 assay shows that knockdown of CBX3 by CBX3 siRNA decreased the proliferation of osteosarcoma MG63 cells when compared to the NC siRNA group. \*P\<0.05 compared with the NC siRNA group. CBX3, chromobox protein homolog 3; CCK-8, Cell-Counting Kit-8.](MMR-19-05-4205-g03){#f4-mmr-19-05-4205}

![CBX3 modulates the cell cycle distribution and apoptosis of osteosarcoma MG63 cells. (A) Flow cytometric analysis of cell cycle distribution of the MG63 cells transfected with CBX3 siRNA or NC siRNA. (B) Flow cytometric analysis of the percentage of apoptotic MG63 cells transfected with CBX3 siRNA or NC siRNA. \*P\<0.05 compared with the NC siRNA group. CBX3, chromobox protein homolog 3.](MMR-19-05-4205-g04){#f5-mmr-19-05-4205}

###### 

Clinicopathological characteristics and expression of CBX3 in the osteosarcoma patient samples.

  Characteristics                No of cases (%)
  ------------------------------ -----------------
  Age (years)                    
    \<20                         61 (62.2)
    ≥20                          37 (37.8)
  Sex                            
    Male                         56 (57.1)
    Female                       42 (42.9)
  Tumor size (cm)                
    \<5                          48 (49)
    ≥5                           50 (51)
  Location                       
    Upper limb bone              36 (36.7)
    Lower limb bone              62 (63.3)
  Clinical stage                 
    I/II                         39 (39.8)
    III/IV                       59 (60.2)
  Pathological differentiation   
    Well/Moderately              45 (45.9)
    Poor                         53 (54.1)
  Response to chemotherapy       
    Good                         54 (55.1)
    Poor                         44 (44.9)
  Lymph node metastasis          
    Absence                      58 (59.2)
    Presence                     40 (40.8)
  Distant metastasis             
    Absence                      72 (73.5)
    Presence                     26 (26.5)
  Recurrence                     
    Absence                      44 (44.9)
    Presence                     54 (55.1)
  Expression of CBX3             
    Low expression               49 (50)
    High expression              49 (50)

CBX3, chromobox protein homolog 3.

###### 

Correlation between CBX3 expression and the clinicopathological characteristics of the osteosarcoma patients.

                                 CBX3 expression        
  ------------------------------ ----------------- ---- ----------
  Age (years)                                           
    \<20                         30                31   0.835
    ≥20                          19                18   
  Sex                                                   
    Male                         30                26   0.414
    Female                       19                23   
  Tumor size (cm)                                       
  \<5                            29                19   0.043
  ≥5                             20                30   
  Location                                              
    Upper limb bone              32                39   0.675
    Lower limb bone              17                19   
  Clinical stage                                        
    I/II                         29                10   \<0.0001
    III/IV                       20                39   
  Pathological differentiation                          
    Well/Moderately              22                23   0.839
    Poor                         27                26   
  Response to chemotherapy                              
    Good                         31                23   0.104
    Poor                         18                26   
  Lymph node metastasis                                 
    Absence                      32                26   0.218
    Presence                     17                23   
  Distant metastasis                                    
    Absence                      41                31   0.022
    Presence                     8                 18   
  Recurrence                                            
    Absence                      23                21   0.685
    Presence                     26                28   

CBX3, chromobox protein homolog 3.

###### 

Spearman analysis of the correlation between CBX3 expression and clinicopathological characteristics of the osteosarcoma patients.

  Characteristics                  Spearman correlation   P-value
  -------------------------------- ---------------------- ---------
  Age                              −0.21                  0.837
    Sex                            0.082                  0.419
    Tumor size                     0.204                  0.044
  Location                         0.042                  0.679
    Clinical stage                 0.396                  \<0.001
    Pathological differentiation   −0.02                  0.841
  Response to chemotherapy         0.164                  0.106
    Lymph node metastasis          0.125                  0.222
    Distant metastasis             0.231                  0.022
  Recurrence                       0.041                  0.688

CBX3, chromobox protein homolog 3.

###### 

Univariate and multivariate analyses for overall survival in the osteosarcoma patients.

                                 Univariate analysis   Multivariate analysis                                         
  ------------------------------ --------------------- ----------------------- --------- -------- ------------------ ---------
  Age                            0.784                 (0.422--1.458)          0.443     0.834    (0.408--1.706)     0.619
  Sex                            1.405                 (0.769--2.566)          0.268     0.758    (0.353--1.627)     0.477
  Tumor size                     1.114                 (0.614--2.021)          0.723     3.099    (1.406--6.833)     0.005
  Location                       0.858                 (0.458--1.608)          0.632     0.876    (0.402--1.913)     0.741
  Clinical stage                 1.512                 (0.821--2.786)          0.184     1.134    (0.519--2.478)     0.753
  Pathological differentiation   0.849                 (0.464--1.553)          0.594     1.042    (0.536--2.024)     0.904
  Response to chemotherapy       1.101                 (0.600--2.022)          0.756     0.53     (0.242--1.158)     0.111
  Lymph node metastasis          2.288                 (1.234--4.243)          0.009     2.249    (1.147--4.407)     0.018
  Distant metastasis             2.006                 (1.011--3.982)          0.046     1.562    (0.694--3.517)     0.281
  Recurrence                     15.06                 (3.601--62.989)         \<0.001   27.656   (6.089--125.616)   \<0.001
  Expression of CBX3             3.534                 (1.808--6.909)          \<0.001   4.259    (1.878--9.660)     0.001

CBX3, chromobox protein homolog 3; CI, confidence interval.

###### 

Univariate and multivariate analyses for disease-free survival in osteosarcoma patients.

                                 Univariate analysis   Multivariate analysis                                    
  ------------------------------ --------------------- ----------------------- ------- ------- ---------------- -------
  Age                            0.77                  (0.440--1.348)          0.360   0.743   (0.409--1.349)   0.329
  Sex                            1.434                 (0.839--2.450)          0.188   1.624   (0.890--2.962)   0.114
  Tumor size                     0.785                 (0.457--1.345)          0.378   0.61    (0.323--1.150)   0.127
  Location                       0.573                 (0.573--1.734)          0.996   0.863   (0.452--1.647)   0.655
  Clinical stage                 1.372                 (0.793--2.377)          0.258   1.365   (0.704--2.645)   0.257
  Pathological differentiation   0.851                 (0.495--1.465)          0.561   0.683   (0.373--1.250)   0.216
  Response to chemotherapy       1.305                 (0.763--2.230)          0.331   1.156   (0.628--2.127)   0.641
  Lymph node metastasis          1.626                 (0.926--2.857)          0.091   1.452   (0.795--2.651)   0.225
  Distant metastasis             1.68                  (0.922--3.061)          0.090   1.327   (0.647--2.723)   0.441
  Expression of CBX3             2.257                 (1.291--3.946)          0.004   1.902   (1.007--3.591)   0.048

CBX3, chromobox protein homolog 3; CI, confidence interval.
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